Johnson & Johnson (NYSE:JNJ) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share guidance of $8.00-8.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.10. The company issued revenue guidance of $81.0-81.8 billion, compared to the consensus revenue estimate of $81.18 billion.

A number of brokerages have commented on JNJ. Vetr lowered shares of Johnson & Johnson from a hold rating to a sell rating and set a $124.55 price target for the company. in a research note on Thursday, April 5th. JPMorgan Chase lowered shares of Johnson & Johnson from an overweight rating to a neutral rating in a research note on Tuesday, January 2nd. Zacks Investment Research upgraded shares of Johnson & Johnson from a hold rating to a buy rating and set a $145.00 price target for the company in a research note on Wednesday, April 11th. Jefferies Group set a $165.00 price target on shares of Johnson & Johnson and gave the company a buy rating in a research note on Monday, February 26th. Finally, BTIG Research restated a sell rating and set a $110.00 price target on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Five analysts have rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of Hold and an average price target of $144.03.

How to Become a New Pot Stock Millionaire

NYSE JNJ opened at $133.15 on Tuesday. Johnson & Johnson has a 1 year low of $120.95 and a 1 year high of $148.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. The firm has a market capitalization of $350,440.66, a PE ratio of 18.23, a PEG ratio of 2.08 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.01 by $0.05. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The firm had revenue of $20.01 billion during the quarter, compared to analyst estimates of $19.50 billion. During the same quarter in the prior year, the business posted $1.83 EPS. The business’s revenue was up 12.6% compared to the same quarter last year. analysts forecast that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

In related news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.22% of the company’s stock.

Large investors have recently modified their holdings of the stock. Premier Asset Management LLC boosted its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after buying an additional 12 shares during the last quarter. LMR Partners LLP purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth about $2,784,000. Dupont Capital Management Corp boosted its holdings in shares of Johnson & Johnson by 19.5% in the 2nd quarter. Dupont Capital Management Corp now owns 330,122 shares of the company’s stock worth $43,672,000 after buying an additional 53,912 shares during the last quarter. QV Investors Inc. boosted its holdings in shares of Johnson & Johnson by 6.7% in the 2nd quarter. QV Investors Inc. now owns 36,565 shares of the company’s stock worth $4,837,000 after buying an additional 2,310 shares during the last quarter. Finally, S. R. Schill & Associates boosted its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. S. R. Schill & Associates now owns 10,494 shares of the company’s stock worth $1,388,000 after buying an additional 40 shares during the last quarter. 67.23% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/04/17/johnson-johnson-jnj-updates-fy18-earnings-guidance.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.